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Activation of toll-like receptors (TLRs) on cells of the innate immune system initiates, ampliﬁes, and directs the
antigen-speciﬁc acquired immune response. Ligands that stimulate TLRs, therefore, represent potential immune
adjuvants. In this study, a potent TLR7 agonist was conjugated to phospholipids, poly(ethylene glycol) (PEG), or
phospholipid-PEG via a versatile benzoic acid functional group. Compared to the unmodiﬁed TLR7 agonist,
each conjugate displayed a distinctive immunological proﬁle in vitro and in vivo. In mouse macrophages and
human peripheral blood mononuclear cells, the phospholipid TLR7 agonist conjugate was at least 100-fold more
potent than the free TLR7 ligands, while the potency of PEG-phospholipid conjugate was similar to that of the
unmodiﬁed TLR7 agonist. When administered systemically in mice, the phospholipid and phospholipid-PEG
TLR7 conjugates induced prolonged increases in the levels of proinﬂammatory cytokines in serum, compared to
the unmodiﬁed TLR7 activator. When the conjugates were used as adjuvants during vaccination, only the
phospholipid TLR7 agonist conjugates induced both Th1 and Th2 antigen-speciﬁc immune responses. These data
show that the immunostimulatory activity of a TLR7 ligand can be ampliﬁed and focused by conjugation, thus
broadening the potential therapeutic application of these agents.
INTRODUCTION
Toll-like receptors (TLRs) are pattern recognition molecules
present on diverse cell types that recognize common ligands in
microbes such as bacteria, viruses, and fungi (1). Various TLRs
interact with lipoprotein (TLR2), double-stranded RNA (TLR3),
lipopolysaccharide (LPS, TLR4), ﬂagellin (TLR5), single-
stranded RNA (TLR7/8), and unmethylated CpG DNA (TLR9).
All TLRs, except TLR3, signal through the myeloid differentia-
tion primary response gene 88 (MyD88) adapter protein,
resulting in the activation of NF-κB and the cytokine genes that
it regulates (2).
The active form of TLR7 is located mainly in the endosomal
compartment of innate immune cells, including dendritic cells,
mast cells, and B lymphocytes (3, 4). The natural ligand for
TLR7 was identiﬁed as guanine and uridine-rich single-stranded
RNA (5). In addition, several low molecular weight activators
of TLR7 have been discovered, including imidazoquinolines,
and purine-like molecules (3, 6, 7). Among the latter, 9-benzyl-
8-hydroxy-2-(2-methoxyethoxy) adenine (SM360320; desig-
nated here as SM) has been shown to be a potent and speciﬁc
TLR7 agonist (8). In a previous study, we synthesized a
derivative of SM-designated UC1V150, in which the aldehyde
functional group on the benzyl moiety enabled coupling the
agonist to different auxiliary chemical entities through a
bifunctional linker molecule containing a hydrazine and N-
hydroxysuccinimide activated ester function (9). Conjugation
to mouse serum albumin (MSA) increased potency by 10- to
100-fold and improved in vivo pharmacodynamics, compared
with the free drug (9). Moreover, the conjugate (MSA-UC1
V150) could be delivered effectively to the respiratory system
by intranasal or intratracheal administration, without inducing
a systemic cytokine syndrome. Drug delivery by the intranasal
route was effective in reducing mortality in mouse models of
bacterial and viral infection (9).
An important aspect of TLR biology is the connection
between receptor localization, cell activation, and cytokine
production. TLR7 and TLR9 are only active when proteolyti-
cally processed and loaded into endosomes (10–12). The
conjugation of various chemical entities to phospholipids is
known to facilitate endocytosis. Therefore, we hypothesized that
conjugation of a TLR7 activator to a phospholipid would
enhance innate immune activation. The conjugation of drugs
to poly(ethylene glycol) can promote their circulation time in
the blood and potentially increase solubility in water (13). It
was therefore of interest to determine if conjugation of a TLR7
agonist to PEG could alter its in vivo pharmacodynamics.
EXPERIMENTAL PROCEDURES
Materials. 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine
(DOPE) was purchased from Avanti Polar Lipids (Alabaster,
AL). All other reagents were purchased as at least reagent grade
from Sigma-Aldrich (St. Louis, MO) without further puriﬁcation.
Solvents were purchased from Fischer Scientiﬁc (Pittsburgh,
PA) and were either used as purchased or redistilled with an
appropriate drying agent. Ovalbumin (OVA, grade V) was
purchased from Sigma-Aldrich.
Endotoxin levels in the reagents and conjugates for experi-
ments of immunological activities were measured using the
QCL1000 end point chromogenic Limulus Amoebocyte Lysate
(LAL) assay purchased from BioWhittaker (Walkerville, MD).
Reagents that contained less than 1 pg endotoxin per µg protein
or drug were used throughout the experiments. Since DOPE
gave false positive results in the chromogenic endotoxin assay,
bone marrow derived macrophages (BMDM) from lipopolysac-
charide unresponsive mutant mice (C3H/HeJ) were used to test
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The levels of cytokine production by bone marrow derived
mononuclear cells from C3H/HeJ mice were similar to the levels
in cells derived from the wild-type C3H/HeOuJ strain, indicating
that endotoxin contamination was negligible (Supporting In-
formation Figure 1).
All conjugates were stored at -80 C° as dry powders. The
conjugates were dissolved in DMSO at 100 mM and further
diluted before immunological assays.
Instrumentation. Analytical TLC was performed using
precoated TLC silica gel 60 F254 aluminum sheets purchased
from EMD (Gibbstown, NJ) and visualized using UV light.
Flash chromatography was carried out on EMD silica gel 60
(40-63 µm) using the speciﬁed solvent system. Chromatogra-
phy and mass spectra (ESI) for compounds without phospho-
lipids were recorded on a 1100 LC/MSD (Agilent Technologies,
Inc., Santa Clara, CA) with a Supelco Discovery HS C18
column (Sigma-Aldrich) with purity above 98% by percent area.
Mass spectra (ESI) of phospholipid-containing compounds were
recorded on a Finnigan LCQDECA (Thermo Fisher Scientiﬁc
Inc., Waltham, MA). 1H NMR spectra were obtained on a
Varian Mercury Plus 400 (Varian, Inc., Palo Alto, CA). The
chemical shifts are expressed in parts per million (ppm) using
suitable deuterated NMR solvents in reference to TMS at 0 ppm.
UV absorbance for solubility experiments were measured using
a NanoDrop ND-1000 spectrophotometer (Wilmington, DE).
4-{[6-Amino-2-(2-methoxyethoxy)-8-oxo-7H-purin-9(8H)-
yl]methyl}benzoic Acid (5). To 4-{[6-amino-8-methoxy-2-(2-
methoxyethoxy)-9H-purin-9-yl]methyl}benzonitrile (1) (0.10 g,
0.28 mmol) was added 1:1 ethanol/10M NaOH (20 mL) and
reﬂuxed for 8 h. The reaction mixture was allowed to cool and
acidiﬁed to pH 2 with conc HCl. The aqueous solution was
extracted with dichloromethane (DCM) (3 × 20 mL), dried over
MgSO4, and evaporated in vitro to yield a mixture of the 8-oxo-
9-benzoic acid (5), 8-methoxy-9-benzoic acid, and 8-oxo-9-ethyl
benzoate. Once dried, the products were dissolved in CH3CN
(25 mL) and NaI (0.14 g, 0.96 mmol) was added. To this
solution was added chlorotrimethylsilane (12 µL, 0.96 mmol)
dropwise with stirring. The reaction mixture was heated at 40
°C for 4 h, then cooled, ﬁltered, and washed with water (20
mL) and then diethyl ether (20 mL) to obtain a white solid in
85% yield. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 10.33 (s,
1H), 7.89 (d, J ) 8 Hz, 2H), 7.37 (d, J ) 8 Hz, 2H), 6.65 (s,
2H), 4.92 (s, 2H), 4.24 (t, J ) 4 Hz, 2H), 3.56 (t, J ) 4 Hz,
2H), 3.25 (s, 3H). Retention time (Rt) on HPLC ) 14.3 min.
ESI-MS (positive ion mode): calculated for C16H17N5O5 m/z
[M+1] 360.34; found 360.24.
2-(4-{[6-Amino-2-(2-methoxyethoxy)-8-oxo-7H-purin-9(8H)-
yl]methyl}benzamido)ethyl 2,3-Bis(oleoyloxy)propyl Phosphate
(6). To a solution of compound 5 (0.022 g, 0.06 mmol) in
anhydrous N,N-dimethylmethanamide (DMF) (1 mL) was added
O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexaﬂu-
orophosphate (HATU) (0.026 g, 0.067 mmol) and anhydrous
triethylamine (TEA) (17.0 µL, 0.12 mmol). A solution of 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (0.05 g, 0.067 mmol)
in anhydrous 1:1 DCM/DMF (1 mL) was prepared and slowly
added to the reaction mixture. The reaction mixture was stirred
at room temperature until completion and then evaporated in
vitro. The product was puriﬁed by ﬂash chromatography using
15% methanol (MeOH) in DCM to give 0.038 g of white solid
in 58% yield. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.7 (s,
1H), 7.87 (d, J ) 8.3 Hz, 2H), 7.32 (d, J ) 8.3 Hz, 2H), 6.61
(s, 2H), 5.30 (m, 4H), 5.05 (m, 1H), 4.88 (s, 2H), 4.26 (m, 4H),
4.06 (m, 1H), 3.77 (m, 4H), 3.57 (m, 2H), 3.35 (m, 2H), 3.26
(s, 3H), 2.23 (m, 4H), 1.95 (m, 8H), 1.46 (m, 4H), 1.22 (m,
40H), 0.83 (m, 6H). ESI-MS (negative ion mode): calculated
for C57H92N6O12P m/z [M-1] 1083.35; found 1083.75. HR-ESI-
FT-MS (positive ion mode): calculated for C57H92N6O12PNa m/z
[M+Na+1] 1107.6481; found 1107.6477.
4-{[6-Amino-8-hydroxy-2-(2-methoxyethoxy)-9H-purin-9-yl]-
methyl}-N-(32-azido-3,6,9,12,15,18,21,24,27,30-decaoxadotria-
contyl)benzamide (7). To a solution of compound 5 (0.100 g,
0.278 mmol) in anhydrous DMF (5 mL) was added HATU
(0.117 g, 0.306 mmol) and anhydrous TEA (77.014 µL, 0.556
mmol). A solution of O-(2-aminoethyl)-O′-(2-azidoethyl)nona-
ethylene glycol (0.150 g, 0.306 mmol) in anhydrous DMF (1
mL) was prepared and slowly added to the reaction mixture.
The reaction mixture was stirred at room temperature until
completion and then evaporated in vitro. The product was
puriﬁed by ﬂash chromatography using 5% MeOH in DCM to
give 0.224 g of an opaque oil in 93% yield. Rt ) 12 min. 1H
NMR (400 MHz, DMSO-d6) δ (ppm): 10.01 (s, 1H), 8.45 (t, J
) 5.6 Hz, 1H), 7.78 (d, J ) 8.3 Hz, 2H), 7.35 (d, J ) 8.3 Hz,
2H), 6.49 (s, 2H), 4.90 (s, 2H), 4.25 (t, J ) 4 Hz, 2H), 3.57
(m, 4H), 3.5 (m, 36H), 3.4 (M, 6H), 3.26 (s, 3H). ESI-MS
(positive ion mode): calculated for C38H61N9O14 m/z [M+1]
868.94; found 868.59.
3-{1-[1-(4-{[6-Amino-8-hydroxy-2-(2-methoxyethoxy)-9H-pu-
rin-9-yl]methyl}phenyl)-1-oxo-5,8,11,14,17,20,23,26,29,32-deca-
oxa-2-azatetratriacontan-34-yl]-1H-1,2,3-triazol-4-
yl}propanoic Acid (8). Compound 7 (0.218 g, 0.251 mmol) and
4-pentynoic acid (0.074 g, 0.753 mmol) was dissolved in 1:1
t-butanol/H2O (3 mL). Sodium ascorbate (0.02 g, 100 mmol)
and Cu(OAc)2 (0.009 g,50 mmol) in 1:1 t-butanol/H2O( 1m L )
was slowly added to the reaction mixture and stirred at room
temperature until compound 7 was fully reacted by TLC. The
product was extracted with DCM (10 mL) and H2O (10 mL),
and the organic layer was dried over MgSO4 to give 0.230 g of
an opaque oil in 95% yield. Rt ) 11.5 min. 1H NMR (400 MHz,
DMSO-d6) δ (ppm): 13.48 (s, 1H), 7.76 (d, J ) 8.29 Hz, 2H),
7.75 (s, 1H), 7.23 (d, J ) 8.29, 2H), 4.88 (s, 2H), 4.41 (t, J )
5.12 Hz, 2H), 4.23 (t, J ) 4 Hz, 2H), 3.74 (t, J ) 5.12 Hz,
2H), 3.57 (t, J ) 4 Hz, 2H), 3.51 (m, 8H), 3.42 (m, 36H), 3.26
(s, 3H), 2.79 (t, J ) 7.56 Hz, 2H), 2.24 (t, J ) 7.56 Hz, 2H).
ESI-MS (positive ion mode): calculated for C43H67N9O16 m/z
[M+1] 966.04; found 966.67.
2-(3-{1-[1-(4-{[6-Amino-8-hydroxy-2-(2-methoxyethoxy)-9H-
purin-9-yl]methyl}phenyl)-1-oxo-5,8,11,14,17,20,23,26,29,32-de-
caoxa-2-azatetratriacontan-34-yl]-1H-1,2,3triazole-4-
yl}propanamido)ethyl 2,3-Bis(oleoyloxy)propyl Phosphate (9).
To a solution of compound 8 (96 mg, 0.1 mmol) and HATU
(42 mg, 0.11 mmol) in anhydrous DMF (1 mL) was added
anhydrous TEA (2.7 uL, 0.2 mmol). A solution of DOPE (81.4
mg, 0.11 mmol) in 1:1 DCM/DMF (1 mL) was added dropwise
to the reaction mixture and stirred at room temperature until
completion. Upon completion, the product was isolated by
evaporation in vitro followed by ﬂash chromatography using
15% MeOH in DCM to give 155 mg of opaque oil in 92%
yield. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.5 (s, 2H),
8.39 (s, 1H), 7.79 (m, 3H), 7.33 (d, J ) 6.23 Hz, 2H), 6.91 (s,
2H), 5.31 (m, 4H), 5.05 (m, 1H), 4.89 (s, 2H), 4.46 (m, 2H),
4.23 (m, 4H), 4.08 (t, J ) 8 Hz, 2 H), 3.76 (m, 4H), 3.63 (t, J
) 8 Hz, 2H), 3.56 (t, J ) 8 Hz, 2H), 3.48 (m, 36H), 3.26 (m,
5H), 3.17 (m, 2H), 2.82 (t, J ) 8 Hz, 2H), 2.39 (t, J ) 8 Hz,
2H), 2.24 (m, 4H), 1.96 (m, 8H), 1.48 (m, 4H), 1.23 (m, 40H),
0.84 (m, 6H). ESI-MS (positive ion mode): calculated for
C84H142N10O23P m/z [M+1] 1691.05; found 1692.82.
Mice. 6-8 week old female C57BL/6 mice were purchased
from Charles River Laboratories (San Diego, CA). C3H/HeJ
and C3H/HeOuJ mice were purchased from The Jackson
Laboratories (Bar Harbor, ME). TLR7 deﬁcient mice were a
gift from Dr. S. Akira, (Osaka University, Osaka, Japan) and
were backcrossed ten generations onto the C57BL/6 background.
Animals were bred and maintained at UCSD in rooms at 22 (
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procedures and protocols were approved by the Institutional
Animal Care and Use Committee.
InVitroMeasurementsofCytokineInduction.TheRAW264.7
(mouse leukemic monocyte macrophage cell line) was obtained
from the ATCC (Rockville, MD) and cultured in DMEM (Irvine
Scientiﬁc, Irvine, CA) supplemented with 10% heat-inactivated
fetal bovine serum, 2 mM L-glutamine, and 100 U/mL penicillin/
100 µg/mL streptomycin. BMDM were prepared from C57BL/
6, TLR7 deﬁcient, C3H/HeJ, and C3H/HeOuJ mice as described
(9). The cells (1 × 106/mL) were incubated with the conjugates
f o r1 8ha t3 7°C, 5% CO2, and culture supernatants were
collected. The levels of cytokines (IL-6, IL-12, or TNFR)i n
the supernatants were determined by ELISA (BD Biosciences
Pharmingen, La Jolla, CA) (12). Minimum detection levels of
these cytokines were 15 pg/mL, respectively.
Human blood peripheral mononuclear cells (PBMC) were
isolated from human buffy coats obtained from The San Diego
Blood Bank (San Diego, CA) as described previously (11).
PBMC (1 × 106/mL) were incubated with various compounds
f o r1 8ha t3 7°C, 5% CO2, and culture supernatants were
collected. The levels of cytokines (IL-6, TNFR,o rI F N R1) in
the supernatants were determined by Luminex bead assays
(Invitrogen, Carlesbad, CA) due to the relatively small sample
volume. The minimum detection levels of IL-6, TNFR, and
IFNR1 were 6 pg/mL, 10 pg/mL, and 15 pg/mL, respectively.
In Vivo Experimental Procedures. For in vivo pharmacoki-
netic experiments, 6 to 8 week old C57BL/6 mice were
intravenously injected with the TLR7 agonist and its conjugates
(40 nmol 4a or 200 nmol SM, 6, 8,o r9 per mouse as described
in the ﬁgure legends). The solubility was measured in 10%
DMSO in saline at room temperature for 30 min at a maximum
theoretical concentration of 1 mM. The aqueous concentrations
of compounds SM, 6, 8, and 9 were measured by UV
absorption, and the concentration was derived by comparison
to standard curves with four calibration concentrations in DMSO
(Supporting Information Table 1). The solutions were homo-
geneous, and no precipitates were noted prior to i.v. administra-
tion. Blood samples were collected 2, 4, 6, 24, or 48 h after the
injections. Sera were separated and kept at -20 °C until use.
The levels of cytokines in the sera were measured by Luminex
bead microassay due to the small sample volume. The minimum
detection levels of IL-6 and TNFR were 5 pg/mL and 10 pg/
mL, respectively.
For the adjuvanticity experiments, mice were subcutaneously
immunized with 20 µg ovalbumin (OVA) with 10 nmol of TLR7
equivalent dose per mouse in various TLR7 conjugates on days
0 and 7. A TLR9 activating immunostimulatory oligonucleotide
sequence (ISS-ODN, 1018) was used as a positive control for
a Th1 inducing adjuvant (10). Sera were collected on days 0,
7, 14, 21, 28, 42, and 56. Mice immunized with saline or OVA
mixed with vehicle served as controls. Mice were sacriﬁced on
day 56, and the spleens were harvested. Approximately 2.5 ×
106/mL spleen cells were aliquoted into round-bottom tissue
culture microtiter plates in triplicate in a total volume of 200
µL RPMI 1640 complete medium [RPMI1640 (Irvine Scientiﬁc,
Irvine, CA) supplemented with 10% heat-inactivated FCS, 2
mM L-glutamine, and 100 U/mL penicillin/100 µg/mL strep-
tomycin] and restimulated with either 100 µg/mL OVA or
medium alone. Cultures were then incubated at 37 °C, 5% CO2,
and supernatants harvested after 72 h. The levels of IFNγ in
the culture supernatants were measured by ELISA (BD Bio-
science PharMingen) as per the manufacturer’s instructions (14).
The average total spleen cell numbers in each group were
calculated and compared to the control group to monitor spleen
cell proliferation.
Anti-OVA antibodies of the IgG subclasses, IgGl and IgG2a,
were measured by ELISA, as described (12). Each ELISA plate
contained a titration of a previously quantitated serum to
generate a standard curve. The titer of this standard was
calculated as the highest dilution of serum that gave an
absorbance reading that was double the background. The various
sera samples were tested at a 1:100 dilution. The results are
expressed in units per mL, calculated based on the units/mL of
the standard serum, and represent the mean ( SEM of ﬁve
animals in each group.
In some experiments, the site of injection was examined 24 h
after immunization for signs of inﬂammation or local reaction.
Mice were observed for locomotor activity to assess a “sickness”
response to immunization and then weighed weekly.
Histological Examination. In the adjuvanticity experiments,
the spleens, lungs, livers, hearts, and kidneys were collected
on day 56. The organs were ﬁxed in 10% buffered formalin
(Fisher Scientiﬁc) and embedded in parafﬁn. Sections 5 µm thick
were stained with hematoxylin and eosin (H&E) and evaluated
under the microscope.
Statistical Analysis. A software package (Prism 4.0, Graph-
Pad, San Diego CA) was used for statistical analyses including
regression analyses. Data were plotted and ﬁtted by nonlinear
regression assuming a Gaussian distribution with uniform
standard deviations between groups. The statistical differences
were analyzed by two-way ANOVA with Bonferroni’s post hoc,
Dunnett’s post hoc, or Student’s t test. A value of P < 0.05 was
considered statistically signiﬁcant.
RESULTS
Chemical Synthesis. The synthesis of compound 4 from
compound 1 yielded a consistent conjugation ratio of 5:1 UC1
V150 to MSA protein (9). Basic hydrolysis of the 9-benzylnitrile
of compound 1 (8) provided a versatile benzoic acid functional
group (5) in 85% yield and allowed for the assembly of
conjugates 6, 8, and 9 (Scheme 1). The benzoic acid was coupled
with DOPE by activation with HATU in the presence of TEA
in anhydrous DMF to give compound 6 in 58% yield. Due to
the difﬁculty in dissolution of compound 6 in suitable solvents
for testing, a PEG spacer was coupled to provide improved
solubility. A readily available amine/azide bifunctional PEG was
coupled to the benzoic acid by activation with HATU in the
presence of TEA in anhydrous DMF to give compound 7 in
93% yield. The formation of a 1,2,3-triazole through a copper(I)-
catalyzed azide-alkyne cycloaddition with 4-pentynoic acid
gave compound 8 in 95% yield. Finally, compound 9 was
prepared by HATU activated amide formation with DOPE and
compound 8 (92% yield).
Cytokine Induction by a Phospholipid-Conjugated TLR7
Agonist. The in vitro potency of the phospholipids TLR agonist
conjugate (6), PEG-TLR7 agonist conjugate (8), PEG-phos-
pholipid (9) conjugate, and the MSA-TLR7 agonist conjugate
were compared using the murine macrophage cell line, RAW264,
and primary bone marrow derived macrophages (BMDM)
(Figure 1A,B). The respective cells were stimulated for 18 h
with serially diluted TLR7 agonist conjugates, and the levels
of cytokines released in the media were measured by ELISA
and compared to the unconjugated TLR7 agonist (SM).
As previously shown, the MSA-TLR7 agonist conjugate (4a)
was approximately 100-fold more potent as a cytokine inducer
compared to the unconjugated agonist. In the same system, the
phospholipid-TLR7 conjugate was 10-fold more potent, when
normalized to the molar level of the pharmacophore (P < 0.0001
compared to unconjugated TLR7 agonist in RAW cells and
BMDM). Although the PEG-TLR7 agonist conjugates (8)
showed less potency compared to the unconjugated TLR7
agonist (SM)( P < 0.001 in RAW cells), the hybrid phospho-
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(SM). Equivalent concentrations of MSA, phospholipid, or PEG,
processed without TLR7 conjugation, induced minimal or no
cytokine levels in RAW264.7 cells and BMDM, respectively
(data not shown).
To conﬁrm that the conjugated forms of the TLR7 agonist
stimulated exclusively via TLR7 activation, BMDM derived
from TLR7 deﬁcient mice were analyzed (Figure 1C,D).
Compounds 4a, 6, 8, 9, and SM induced little or no IL-12 and
IL-6 production in the TLR7 deﬁcient cells, whereas these
conjugates were active in wild-type BMDM. To assess the
immunological effects of the conjugates in human cells, PBMC
from three separate donors were treated with the different agents,
and the levels of IL-6 and IFNR1 released into the supernatants
were determined (Figure 2A,B). Human serum albumin (HSA)
conjugated to the TLR7 agonist (4b) was used instead of MSA-
Scheme 1. Synthesis of the Phospholipid- (6), PEG- (8), Phospholipid-PEG (9) TLR7 Conjugates
a
a (a) Lithium N,N′-methylethylenediaminoaluminum hydrides THF, 0° C; (b) NaI, chlorotrimethylsilane, CH3CN, r.t; (c) PBS, r.t.; (d) NaOH:
EtOH 1:1, reﬂux; (e) DOPE, HATU, triethylamine,DMF/DCM 1:1, r.t.; (f) O-(2-Aminoethyl)-O2-(2-azidoethyl)nonaethylene glycol, HATU,
triethylamine, DMF, r.t.; (g) 4-pentyonic acid, sodium ascorbate, Cu(OAc)2, t-BuOH/H2O/THF 2:2:1, r.t; (h) DOPE, HATU, triethylamine, DMF/
DCM 1:1, r.t.
Figure 1. In vitro immunological characterization of TLR7 conjugates
in murine macrophages. 1 × 106/mL RAW 264.7 cells (A), or 0.5 ×
106/mL BMDM derived from wild-type (B-D) or TLR7 deﬁcient mice
(C,D) were incubated with serially diluted TLR7 conjugates for 18 h.
Serial dilutions of SM (triangle), 6 (gray circle), 8 (solid square), and
9 (ex) were prepared (steps of 1:5) starting from 10 µM. 4a (gray
rhombus) was serially diluted (steps of 1:5), starting from 0.1 µM. The
levels of TNFR, IL-6, and IL-12 in the culture supernatants were
measured by ELISA. Data are mean ( SEM of triplicates and are
representatives of three independent experiments. P < 0.001 by two-
way ANOVA with Bonferroni post hoc test in comparison between
SM and 6. * denotes P < 0.01 by Student’s t test compared to the
corresponding data of wild-type macrophages.
Figure 2. In vitro immunological characterization of TLR7 conjugates
in human PBMC. 2 × 106/mL human PBMC were incubated with
serially diluted TLR7 conjugates for 18 h. Serial dilutions of SM
(triangle), 6 (gray circle), 8 (solid square), and 9 (ex) were prepared
(steps of 1:5) starting from 10 µM. 4a (gray rhombus) was serially
diluted (steps of 1:5), starting from 0.1 µM. The levels of IL-6 (A)
and IFNR1 (B) in the culture supernatants were determined by Luminex
assay in duplicate. Data are means ( SEM and are representative of
three independent experiments. The order of potency is 4b > 6 > 9 >
SM ) 8 (P < 0.0005 by two-way ANOVA test for compounds 4b, 6,
9, and SM; P ) 0.2 by two-way ANOVA test for compound 8).
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MSA antibodies. The order of potency of the conjugates was
similar in human PBMC and mouse BMDM (4b > 6 > 9 > SM
) 8) (Figure 2A). Compound 4b induced minimal levels of
IFNR1 in all of the human PBMC samples tested (Figure 2B).
In Vivo Kinetics of Induction of Pro-Inﬂammatory
Cytokines by TLR Agonist Conjugates. To compare the in
vivo immunological properties of the different TLR7 agonist
conjugates, C57BL/6 mice were injected intravenously with the
agents, and cytokine levels in sera were assayed at various time
intervals (Figure 3A,B). On the basis of the results of a previous
study (9), compound 4a was used at a lower concentration (40
nmol per animal) than compounds SM, 6, 8, and 9 (200 nmol
per animal). The maximum induction of TNFR and IL-6 was
observed 2 h after injection with all the TLR7 conjugates (Figure
3A,B). Although the levels of the cytokines induced by the
unconjugated TLR7 agonist (SM) declined rapidly after 2 h,
cytokine induction by compounds 4a, 6, and 9 was sustained
for up to 6 h. Compound 8 induced only a low level of IL-6,
and undetectable TNFR, 6 h after injection (Figure 3B). Sera
from control mice that received saline, MSA, or DOPE revealed
little or no detectable cytokine levels (data not shown).
Phospholipid-TLR7 Agonist Conjugates Promote Rapid
and Long-Lasting Humoral Immune Responses. The adju-
vanticity of the different conjugates was assessed by the levels
and isotypes of antigen-speciﬁc IgG induced after immunization
of mice with ovalbumin (OVA) and drug (15), as well as by
antigen-induced synthesis of interferon γ (IFNγ). Groups of
C57BL/6 (n ) 5 animals per group) were subcutaneously
injected with OVA mixed with the various TLR7 conjugates.
A TLR9 activating immunostimulatory oligonucleotide sequence
(ISS-ODN, 1018) is known to stimulate Th1 immune response
and was used as a positive control for a Th1 inducing adjuvant
(10). The kinetics of OVA-speciﬁc serum IgG1 and G2a on
days 0, 7, 14, 21, 28, 42, and 56 were monitored by immu-
noassay (Figure 4A,B). Induction of IgG was observed as early
as 14 days in mice immunized with OVA and compound 4a or
compound 6 (Figure 4A). The anti-OVA IgG2a levels increased
thereafter in mice immunized with OVA and compound 6, while
the levels in mice immunized with OVA and compound 4a
mixture declined progressively. The spleen cells of mice
immunized with OVA combined with compound 4a or 6
displayed enhanced OVA-speciﬁc IFNγ secretion, compared to
mice immunized with OVA alone or OVA and a TLR9 agonist
(Figure 4C).
Adverse Effects. We previously reported that 150 nmol of
the TLR7 agonist SM induced anorexia and weight loss in mice
after intranasal administration (16). We, therefore, monitored
both body weights and local skin inﬂammation in mice
immunized with the phospholipid-TLR7 agonist conjugate. At
the dose of TLR7 agonist that was an effective adjuvant (10
nmol per mouse), no weight loss or behavioral changes were
noted. Chronic administration of TLR7 agonists can also
stimulate hematopoietic cell proliferation, leading to spleen and
lymph node hyperplasia (17). However, there were no signiﬁcant
differences in the numbers of splenocytes or myeloid cells
between mice immunized with OVA alone, compared to TLR7
agonist conjugates and the saline control mice (Figure 5A).
Figure 3. Kinetics of proinﬂammatory cytokine induction by TLR7 conjugates in vivo. C57BL/6 mice (n ) 5 per group) were intravenously
injected TLR7 conjugates (SM, 200 nmol; 4a, 40 nmol; 6, 200 nmol; 8, 200 nmol; 9, 200 nmol). Serum samples were collected 2, 4, 6, 24, and
48 h after injection. The levels of TNFR (A) and IL-6 (B) were measured by Luminex assay. Data are means ( SEM of ﬁve mice and are
representative of two independent experiments. (C) Control naı ¨ve mice. * denotes p < 0.05 compared to the naı ¨ve mice by one-way ANOVA tests
with Bonferroni post hoc testing.
Figure 4. Adjuvanticity of TLR7 conjugates in vivo. Groups of C57BL/6 (n ) 5 per group) were subcutaneously immunized with 20 µg OVA
mixed with TLR7 conjugates (10 nmol TLR7 equivalent dose per mouse) on days 0 and 7. Sera were collected days 0, 7, 14, 21, 28, 42, and 56.
OVA speciﬁc IgG1 and IgG2a were measured by ELISA (A and B). On day 56, mice were sacriﬁced, and splenocytes were cultured with OVA
(100 µg/mL) in RPMI1640 for 3 d. IFNγ level in the supernatant was measured by ELISA (C). Data are means ( SEM of 5 mice/group and are
representative of 3 independent experiments. * and † denote P < 0.05 and P < 0.01 by one-way ANOVA with Dunnett’s post hoc comparison to
the mice immunized with OVA mixed with vehicle, respectively.
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OVA plus TLR7 agonist conjugate showed no structural
disruption of the white pulp and no increased cellularity in the
red pulp (Figure 5B). Moreover, no signiﬁcant differences were
observed in the histological appearance of the liver, lung, heart,
and kidney samples collected from each group (data not shown).
There was also no signiﬁcant erythema or warmth at the sites
of injection (Figure 5C).
DISCUSSION
TLR7 agonists are not active unless delivered to endosomal
vesicles where the active receptor resides (18). Previous
experiments showed that the conjugation of a TLR7 agonist to
serum albumin greatly increased potency, compared to the
unconjugated drug (9). Presumably, the modiﬁed albumin
quickly interacted with scavenger receptors on macrophages and
dendritic cells, followed by endocytosis. However, modiﬁed
proteins are not generally suitable for adjuvants, as they are
difﬁcult to standardize, store, and administer, and may be
immunogenic. Therefore, we conjugated a TLR7 agonist to
phospholipids (6), which are widely used to deliver drugs to
cells. The phospholipid-TLR7 conjugated was 10-fold more
potent as a cytokine inducer in mouse and human cells,
compared to the unconjugated TLR7 agonist. More importantly,
the phospholipid conjugate was a rapidly acting and potent
adjuvant for vaccination. It induced antibody responses by 14
days after primary immunization and stimulated both antibody
production and antigen speciﬁc interferon production. In
contrast, the conjugation of the same TLR7 agonist to PEG (8)
reduced its potency in vitro, unless a phospholipid moiety was
included in the conjugated molecule (9). Experiments using
TLR7 deﬁcient mouse cells conﬁrmed that all the conjugates
used in this study stimulated immune responses exclusively
through TLR7.
One would normally expect that the same TLR7 activating
pharmacophore, conjugated to different delivery molecules,
would induce comparable patterns of cytokine synthesis.
However, this was clearly not the case. The TLR7 agonist
albumin conjugates (4b) induced high levels of IL-6 in human
blood leukocytes but very low levels of type I interferons. In
contrast, the TLR7 agonist phospholipid conjugate (6) induced
abundant IL-6 and type I interferon. In humans and mice, the
major source of type 1 interferon is plasmacytoid dendritic cells
(pDC) (19), while other dendritic cells, mast cells, and B
lymphocytes can produce IL-6. Furthermore, it is mainly TLRs
in early, newly formed endosomes that are linked to type I
interferon synthesis (20). Interaction of a TLR agonist and its
receptor in the early endosome triggers the interferon induction
pathway, whereas interaction in the late endosome induces
cytokines dependent on the NF-κB pathway, such as TNFR and
IL-6 (20). The results emphasize the complexity of TLR7 signal
transduction, which may be regulated by target cell type,
endosomal localization, and receptor occupancy time. The
conjugation of a TLR7 pharmacophore to different accessory
molecules could affect all these parameters. In particular, the
TLR7 phospholipid conjugate could promote uptake by plas-
macytoid dendritic cells or enhance intracellular persistence of
the ligand in early endosomal vesicles.
It is well-established that the antibody class and subtype
induced by vaccination can be inﬂuenced by the type of
coadministered adjuvant (21). In mice, IgG2 production is a
surrogate marker for activation of Th1-type cells, which also
promote delayed hypersensitivity responses. In contrast, Th2-
type cells preferentially enhance IgG1 synthesis and do not foster
delayed hypersensitivity. However, both antibody and T-cell
mediated delayed hypersensitivity responses are optimally
needed to control many infections. The TLR7 agonist conjugated
to albumin or phospholipid caused rapid elevation of IgG2a
antibodies. However, levels of IgG2a in the mice receiving the
albumin conjugate (4a) declined by three weeks after the last
immunization, while the mice immunized with the phospholipid
conjugates sustained and even increased antigen-speciﬁc IgG2a
levels without further boosting. One possible explanation for
the divergent effects is that the phospholipid conjugate acted
as a depo, delivering the TLR7 activating pharmacophore over
a more prolonged period.
The unconjugated TLR7 active SM molecule is very poorly
soluble in aqueous solutions. Conjugation to poly(ethylene
glycol) (PEG) improved its solubility but decreased its ability
to induce cytokines (Figure 3). However, a hybrid conjugate
Figure 5. Evaluation of possible adverse effects of TLR7 conjugates. C57BL/6 mice were immunized with OVA 20 µg with TLR7 conjugate. On
day 56, mice were sacriﬁced, and the number of total splenocytes was determined (A). The spleens were collected and submitted for histological
examination (×100) (B). The skin at injection sites was inspected 24 h after injection (C). There was no signiﬁcant difference in the splenocyte
number between the mice immunized with OVA plus TLR7 conjugates and the mice immunized with OVA alone (A). Histological examination
of the spleens from mice immunized with OVA mixed with TLR7 conjugates did not show any disruption of the white pulps or increased cellularity
in red pulp (B). The skin at injection sites did not have visible redness (C).
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inducing activity. Vaccination with the hybrid conjugate as
adjuvant induced a signiﬁcant Th2 immune response but a
minimal Th1 response.
Imiquimod, a speciﬁc but relatively weak TLR7 agonist, is
currently approved for treatment of skin disorders such as viral
warts and superﬁcial basal cell carcinomas (22, 23). The TLR7
phospholipid conjugate described here is approximately 1000-
fold more potent as a cytokine inducer. Although the hybrid
conjugate containing both phospholipids and PEG was some-
what less potent, its water solubility renders it useful for
systemic administration. In contrast, the phospholipid conjugate
may be preferable for local administration, where persistent
stimulation of in situ immune cells is desirable. The phospho-
lipid moiety may also facilitate drug penetration through the
epidermal barrier. Thus, the conjugation of a TLR7 agonist to
phospholipid or PEG moieties is a promising strategy to expand
the clinical uses of these agents for infectious, malignant, or
atopic diseases.
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